𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tranylcypromine isomers: Single-dose effects in normal human subjects

✍ Scribed by Clarice Gorenstein; Valentim Gentil

Publisher
Springer
Year
1981
Tongue
English
Weight
381 KB
Volume
75
Category
Article
ISSN
0033-3158

No coin nor oath required. For personal study only.

✦ Synopsis

Moderately high single doses of (+)-and (-)tranylcypromine were given to normal subjects, in the morning and evening, in two double-blind placebo-controlled experiments. Effects were determined up to 24h later by psychological and physiological measures. No significant differences were found on most measures, but the subjects consistently reported stronger effects after the (+)isomer. Both active drugs induced sedative effects when given in the morning. Following the evening administration, delayed sleep onset was reported after the (-)isomer, while the (+)isomer was associated with more awakenings during the night. The mechanisms responsible for these effects are discussed.

πŸ“œ SIMILAR VOLUMES

Human dolasetron pharmacokinetics: I. Di
Human dolasetron pharmacokinetics: I. Disposition following single-dose intravenous administration to normal male subjects
✍ Harold Boxenbaum; Todd Gillespie; Kathleen Heck; William Hahne πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 471 KB πŸ‘ 2 views

Dolasetron is a 5-hydroxytryptamine antagonist active at type 111 receptors; it is presently undergoing clinical evaluation for the reduction/prevention of cancer chemotherapyinduced nausea and vomiting. Following intravenous administration to healthy male subjects of doses ranging from 0.6 to 5 mg

Human dolasetron pharmacokinetics: II Ab
Human dolasetron pharmacokinetics: II Absorption and disposition following single-dose oral administration to normal male subjects
✍ Harold Boxenbaum; Todd Gillespie; Kathleen Heck; William Hahne πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 485 KB πŸ‘ 2 views

## Abstract Dolasetron is a 5‐hydroxytryptamine antagonist active at type III receptors; it is presently undergoing clinical evaluation for the reduction/prevention of cancer chemotherapyinduced nausea and vomiting. A previous study demonstrated that following intravenous administration to healthy